Education And Debate
Foreign free riders and the high price of US medicines
BMJ 2005; 331 doi: https://doi.org/10.1136/bmj.331.7522.958 (Published 20 October 2005) Cite this as: BMJ 2005;331:958Related articles
- This Week In The BMJ Published: 20 October 2005; BMJ 331 doi:10.1136/bmj.331.7522.0-d
- Analysis Published: 07 August 2012; BMJ 345 doi:10.1136/bmj.e4348
- Editorial Published: 16 March 2018; BMJ 360 doi:10.1136/bmj.k1088
- Research Published: 23 October 2019; BMJ 367 doi:10.1136/bmj.l5766
See more
- Introductory AddressProv Med Surg J October 03, 1840, s1-1 (1) 1-4; DOI: https://doi.org/10.1136/bmj.s1-1.1.1
- Report of the Meeting of the Eastern Branch of the Provincial Association at Bury St. Edmond'sProv Med Surg J October 03, 1840, s1-1 (1) 10-13; DOI: https://doi.org/10.1136/bmj.s1-1.1.10
- Mr. Warburton's Bill for the Regulation of the Medical ProfessionProv Med Surg J October 03, 1840, s1-1 (1) 13-15; DOI: https://doi.org/10.1136/bmj.s1-1.1.13
- An Atlas of Plates, illustrative of the Principles and Practice of Obstetric Medicine and Surgery, with descriptive LetterpressProv Med Surg J October 03, 1840, s1-1 (1) 4; DOI: https://doi.org/10.1136/bmj.s1-1.1.4
- A Practical Treatise on the Diseases peculiar to Women, illustrated by Cases, &cProv Med Surg J October 03, 1840, s1-1 (1) 4-5; DOI: https://doi.org/10.1136/bmj.s1-1.1.4-a
Cited by...
- Public sector financial support for late stage discovery of new drugs in the United States: cohort study
- Trump blames free riding foreign states for high US drug prices
- Effectiveness, safety and costs of orphan drugs: an evidence-based review
- The Roles Of Academia, Rare Diseases, And Repurposing In The Development Of The Most Transformative Drugs
- High Cancer Drug Prices in the United States: Reasons and Proposed Solutions
- Why Oncologists Should Support Single-Payer National Health Insurance
- Pharmaceutical research and development: what do we get for all that money?
- Longer Exclusivity Does Not Guarantee Better Drugs
- Global Drug Discovery: Europe Is Ahead
- Misleading Congress about Drug Development: Reply
- Reply to DiMasi, Hansen, and Grabowski
- Misleading Congress about Drug Development